Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)
Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal Carcinoma
Sponsor: Deutsche Krebshilfe e.V., Bonn (Germany)
Listed as NCT06019130, this PHASE2 trial focuses on Nasopharyngeal Cancer and Nasopharyngeal Carcinoma and remains actively recruiting participants. Sponsored by Deutsche Krebshilfe e.V., Bonn (Germany), it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Jun 2024 [monthly]
Recruiting PHASE2
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Deutsche Krebshilfe e.V., Bonn (Germany)
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Berlin, Germany , Bielefeld, Germany , Bonn, Germany , Cologne, Germany , Cottbus, Germany , Dortmund, Germany , Dresden, Germany , Erlangen, Germany , Essen, Germany and 16 more locations